Trial Profile
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M4344 (Formerly VX-803) as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Mar 2023
Price :
$35
*
At a glance
- Drugs Gartisertib (Primary) ; Carboplatin
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors EMD Serono Research & Development Institute; Vertex Pharmaceuticals
- 26 Oct 2021 Status changed from active, no longer recruiting to completed.
- 25 May 2021 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2020 Planned number of patients changed from 85 to 300.